Przejdź do zawartości
Merck

[Clinical course of acute respiratory infection and the state of microbiocenosis of upper respiratory tract in pregnant women].

Zhurnal mikrobiologii, epidemiologii, i immunobiologii (2012-11-21)
M P Kostinov, A K Meshcheriakova, E P Foshina, D A Tarbaeva, A A Savis'ko, E V Zaĭtseva
ABSTRAKT

Evaluate clinical features of the course of acute respiratory infection (ARI) and the state of microbiocenosis of nasopharynx of pregnant women at gestational term of 14 - 26 weeks. At the stage of outpatient therapy of ARI 49 pregnant women at the gestational term of 14 - 26 weeks were examined: group 1--27 individuals consulting at day 1 and receiving Viferon (gel) intranasally for 10 days, group 2--22 individuals consulting at day 2 - 3 and receiving Viferon (gel and suppositorium). Respiratory viral infection was diagnosed by multiplex PCR. Bacteriologic study of discharge from the middle section of the pharynx was performed by the standard technique. ARI in group 1 of pregnant women were regarded as mild severity and persisted for an average of 3 days. In group 2 in 13 (59%) of patients ARI of moderate severity was noted and the recovery occurred at day 6. Pyo-inflammatory diseases of ENT organs appeared in 10 (45.4%) of patients. Respiratory infections were determined in 16 (32.7%) of them: coronaviruses--in 5 (10.2%), rhinoviruses--in 3 (6.2%), respiratory syncytial viruses--in 6 (12.3%), parainfluenza (type 2) and influenza A viruses--1 (2%) both, without significant differences between the observed groups. Streptococcus agalactiae, Staphylococcus aureus, Streptococcus mitis, Moraxella catarrhalis, Corynebacterium spp., Streptococcus pyogenes with the predominance of the latter in 36.7% and 60% of cases, respectively, in pregnant women of the group 2 (p < 0.01), were detected in the microflora of the mucous membrane of the nasopharynx. Viferon preparation therapy prescribed at day 1 of outpatient visit of pregnant women may promote mild course o fARI and prophylaxis of complications of upper respiratory tract.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Interferon α-2b, European Pharmacopoeia (EP) Reference Standard